Morgan Stanley’s Urovant Sciences Ltd. UROV Stock Holding History

Morgan Stanley’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,550	Closed	-$251K	–	7653
2020 Q4	$251K	Buy	+15,550	New	+$193K	﹤0.01%	5478
2020 Q2	–	Sell	-1,000	Closed	-$9K	–	6823
2020 Q1	$9K	Buy	+1,000	New	+$12K	﹤0.01%	6058
2019 Q1	–	Sell	-63	Closed	–	–	6787
2018 Q4	$0	Buy	+63	New	+$573	﹤0.01%	6817

Morgan Stanley's UROV Position: Q1 2021 in Review

Morgan Stanley sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 15,550 shares — an estimated $251K sold.

Morgan Stanley first reported a position in UROV in Q4 2018 and held it in 3 quarters. The position peaked at $251K in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Morgan Stanley reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Morgan Stanley sold 15,550 Urovant Sciences Ltd. shares in Q1 2021, an estimated $251K.
Morgan Stanley first reported a position in Urovant Sciences Ltd. in Q4 2018 and held it in 3 quarters.
Morgan Stanley's Urovant Sciences Ltd. position peaked at $251K in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.